
    
      For the purposes of this study, "study treatment" will refer to the investigational agents,
      tislelizumab and/or pamiparib. A parent study is defined as the original BeiGene sponsored
      clinical trial in which the participant was initially enrolled and received tislelizumab or
      pamiparib treatment or both (with or without other treatments).
    
  